Public health officials in the Democratic Republic of the Congo are accelerating clinical trials for experimental Ebola therapeutics as the current outbreak expands into two new provinces. According to the World Health Organization, 142 confirmed cases have been recorded since late April 2026, marking a significant increase in transmission across the Equateur and Tshuapa regions.
Expanding Clinical Trials for Ebola Treatments
The World Health Organization (WHO) confirmed this week that researchers are prioritizing the deployment of two monoclonal antibody treatments, mAb114 and REGN-EB3, to treatment centers in Mbandaka. These therapies, which received expanded access authorization for emergency use during the 2018-2020 outbreak, are currently being administered to patients under a monitored compassionate use protocol. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, modify, or mimic the immune system’s attack on cells that carry the Ebola virus.
Dr. Jean-Jacques Muyembe, head of the Institut National de Recherche Biomédicale in Kinshasa, stated that the primary objective is to evaluate the efficacy of these treatments in a decentralized setting. Unlike previous trials that relied on centralized hospitals, current efforts focus on mobile clinics located closer to rural clusters of infection. Data from the first 50 patients treated under this decentralized model suggest a mortality rate of 28%, though officials cautioned that these figures are preliminary. In clinical research, decentralized trials are intended to reduce the burden on patients by bringing care to their communities, which is particularly vital in regions where hospital access is restricted by geography or conflict.
Logistical Challenges in Tshuapa and Equateur
The geographical spread into the Tshuapa province has complicated medical supply chains. Health workers report that the lack of paved infrastructure necessitates the use of river transport for cold-chain storage units required to maintain the stability of the therapeutics. Maintaining a cold chain is a critical component of public health logistics, as biological therapeutics like monoclonal antibodies and vaccines can degrade if exposed to high temperatures, rendering them ineffective.
The WHO regional office for Africa reported that 12,000 doses of the rVSV-ZEBOV-GP vaccine have been delivered to the region as of June 10, 2026. This vaccine, manufactured by Merck, is being deployed through a ring vaccination strategy, targeting primary contacts and healthcare workers. A ring vaccination strategy involves identifying and vaccinating all people who have been in contact with an infected individual, as well as the contacts of those contacts. By creating a “ring” of immunized individuals around a case, health officials aim to stop the virus from spreading further. However, local health authorities noted that community resistance to vaccination remains a barrier in remote settlements where misinformation regarding the treatment’s side effects has circulated.
Comparative Data on Transmission Trends
Current case counts show a distinct acceleration compared to the initial surge reported in May 2026. Data published by the DRC Ministry of Health indicates that the reproduction number (R0) for this outbreak currently sits at 1.8, compared to an average of 1.3 during the 2022-2023 outbreaks. The R0, or basic reproduction number, is a mathematical term used to indicate how contagious an infectious disease is; an R0 of 1.8 suggests that each infected person is, on average, passing the virus to nearly two others, which indicates a trend of growth in the total number of cases.
Public health analysts attribute this shift to the high mobility of populations along the Congo River, which has facilitated the movement of the virus between previously isolated villages. While the 2026 figures remain lower than the historical peaks of the 2018 outbreak, the rapid expansion into two provinces has triggered a heightened state of alert from the Africa Centres for Disease Control and Prevention. The Africa CDC plays a coordinating role in supporting member states in their efforts to strengthen health systems and respond to public health emergencies across the continent.
The current spread is compounded by the difficulty of tracing contacts in forest-adjacent communities. We are not just fighting the virus; we are fighting the distance between our clinics and the people who need them most.
Dr. Matshidiso Moeti, WHO Regional Director for Africa
Next Steps for Containment and Research
The international response remains focused on the integration of therapeutic access with active surveillance. The WHO has committed an additional $14 million in emergency funding to bolster laboratory capacity in the Tshuapa province. Surveillance involves the systematic collection, analysis, and interpretation of health data to plan, implement, and evaluate public health practices. By expanding laboratory capacity, officials aim to reduce the “turnaround time” for testing, which allows for faster isolation of positive cases and more efficient contact tracing.
Future containment efforts will rely on the success of these ongoing therapeutic evaluations. Officials plan to release a comprehensive analysis of the treatment outcomes by mid-July 2026. Until then, the focus remains on isolating suspected cases and ensuring the safety of healthcare workers operating in high-transmission zones. These workers typically utilize personal protective equipment (PPE) and strict infection prevention and control (IPC) protocols to minimize the risk of nosocomial, or hospital-acquired, transmission.
Readers should understand that preliminary data from clinical trials are subject to change as more patients are enrolled and more data is analyzed. Clinical evidence must be peer-reviewed and validated across larger, diverse populations to determine definitive safety and efficacy profiles. Consult your healthcare provider if you reside in the affected regions and exhibit symptoms such as high fever, severe headache, or unexplained bleeding. This information is for educational purposes and does not constitute medical advice.
Find more reporting in our Health section.
